Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6723633 | 0.93 | PTGS2 (0.57) | PTGS2PTGS1RXRANR1H2NR1H3 | |
| SCHEMBL6718772 | 0.90 | PTGS2 (0.58) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL6718459 | 0.89 | PTGS2 (0.66) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL6718992 | 0.88 | PTGS2 (0.67) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL6722626 | 0.88 | PTGS2 (0.57) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL6721918 | 0.88 | PTGS2 (0.65) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL6721397 | 0.88 | PTGS2 (0.72) | PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL6725491 | 0.88 | PTGS2 (0.56) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL6734503 | 0.87 | RXRA (0.56) | PTGS2PTGS1RXRANR1H2NR1H3 | |
| SCHEMBL6725929 | 0.87 | PTGS2 (0.61) | PTGS2PTGS1CYP2C9PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| EP-1296971-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
| WO-2001081332-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885PTGS1 4/4885RXRA 876/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885PTGS1 4/4885RXRA 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.